Figure 5.

The four variants do not change the degradation pathway of neuroligin 3 and neuroligin 4X. HEK293 cells expressing GFP‐tagged wild‐type neuroligin (NL3 and NL4X), mutant neuroligin (G426S, G84R, Q162K, and A283T), or positive control (R451C and R87W) were pretreated with the proteasome inhibitor MG132 (10 μmol/L) or the lysosome inhibitor chloroquine (CQ; 100 μmol/L) for 0 hr (untreated) or 10 hr. The accumulation of wild‐type neuroligin, mutant neuroligin, and positive control was evaluated by Western blotting. Beta‐actin was used as a loading control. (a) Degradation pathway assay of mutant neuroligin 3. (b, c) Degradation pathway assay of mutant neuroligin 4X. (d, e) Quantification for the assay of mutant protein degradation pathway. ** referred to p < .001